This white paper was made possible through an unrestricted grant by AstraZeneca Canada Inc.
Between November 2023 and February 2024, Transthyretin Amyloidosis Canada engaged with Canadian patients and caregivers from both a qualitative and quantitative information gathering perspective. From a quantitative standpoint, TAC issued a 23-question online survey which was completed by 30 patients and caregivers from different provinces, including Ontario, Quebec, British Columbia, Alberta, Manitoba and Nova Scotia. From a qualitative perspective, TAC held 12 individual interviews with patients, based off a 25-question questionnaire.